Docmoates: Add medication infobox (Drugbox) to monographs

2026-06-17T16:09:35Z

Add medication infobox (Drugbox) to monographs

← Older revision		Revision as of 16:09, 17 June 2026
Line 1:		Line 1:
			{{Drugbox
			\| name = Non-TNF biologic DMARDs
			\| brand = Rituxan, Actemra, Stelara, Cosentyx, Dupixent, Orencia, Kineret
			\| therapeutic = Biologic immunomodulators
			\| pharmacologic = Monoclonal antibodies and receptor antagonists targeting specific immune pathways (CD20, IL-6, IL-12/23, IL-17, IL-4/13, T-cell costimulation, IL-1)
			\| onset = Effect over weeks; IV or SubQ by agent.
			\| halflife = Long; dosed at intervals from daily (anakinra) to every several weeks or months.
			\| routes = IV, SubQ
			\| highalert = No
			\| blackbox = <span style="color:#b00020;">'''Yes'''</span> (see Safety)
			\| antidote = Supportive care; manage infusion reactions.
			\| pregnancy = Case by case under specialist guidance.
			}}

	<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;">		<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;">
	''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.''		''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.''

Docmoates: NCLEX nursing pharmacology monographs — batch import

2026-06-17T14:06:18Z

NCLEX nursing pharmacology monographs — batch import

New page

<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;">
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.''
</div>

'''Non-TNF biologic DMARDs''' (brand names Rituxan, Actemra, Stelara, Cosentyx, Dupixent, Orencia, Kineret) — Biologic immunomodulators; Monoclonal antibodies and receptor antagonists targeting specific immune pathways (CD20, IL-6, IL-12/23, IL-17, IL-4/13, T-cell costimulation, IL-1).

== Identification ==
* '''Therapeutic class:''' Biologic immunomodulators.
* '''Pharmacologic class:''' Monoclonal antibodies and receptor antagonists targeting specific immune pathways (CD20, IL-6, IL-12/23, IL-17, IL-4/13, T-cell costimulation, IL-1).

== Pharmacology ==
* '''Mechanism of action:''' Each blocks a specific immune target to reduce inflammation.
* '''Onset / peak / duration:''' Effect over weeks; IV or SubQ by agent.
* '''Half-life / therapeutic level:''' Long; dosed at intervals from daily (anakinra) to every several weeks or months.

== Clinical use ==
* '''Indications:''' Rheumatoid arthritis, psoriasis and psoriatic arthritis, inflammatory bowel disease, atopic dermatitis and asthma (dupilumab), certain lymphomas and vasculitis (rituximab).
* '''Usual dose, route, frequency:''' IV infusion (rituximab, tocilizumab, some) or SubQ (others) at agent-specific intervals.
* '''Maximum dose / adjustments:''' Hold for serious infection; screen for tuberculosis and hepatitis as appropriate.

== Safety ==
* '''Contraindications:''' Active serious infection; agent-specific cautions.
* '''Black box warning:''' Rituximab carries boxed warnings for fatal infusion reactions, severe mucocutaneous reactions, hepatitis B reactivation, and progressive multifocal leukoencephalopathy; tocilizumab carries a boxed warning for serious infections.
* '''Interactions:''' Other immunosuppressants (infection), live vaccines (avoid), tocilizumab affects CYP substrates.
* '''Pregnancy / lactation:''' Case by case under specialist guidance.
* '''High-alert:''' No.

== Adverse effects ==
* '''Common side effects:''' Infusion or injection reactions, upper respiratory infections, headache.
* '''Serious effects to report:''' Serious infections, hepatitis B reactivation (rituximab), neurologic symptoms (PML), GI perforation (tocilizumab, with diverticulitis), conjunctivitis (dupilumab).
* '''Antidote / reversal:''' Supportive care; manage infusion reactions.

== Nursing process ==
* '''Assessment before administration:''' Infection screening, hepatitis B status (rituximab), premedication for infusions, vaccination status.
* '''Interventions during therapy:''' Premedicate and monitor closely during rituximab infusions; avoid live vaccines; hold for infection.
* '''Monitor:''' Infusion reactions, infection, hepatitis (rituximab), neurologic status.
* '''Evaluation / expected outcome:''' Reduced disease activity.

== Patient teaching ==
* '''Patient teaching:''' Report infections and infusion reactions; avoid live vaccines.
* '''Notify provider if:''' Fever or infection, severe infusion reaction, new neurologic symptoms.
* '''Administration tips:''' Infusion monitoring and premedication for IV agents; SubQ rotation for others.

[[Category:Biologic DMARDs]]

Non-TNF biologic DMARDs - Revision history

Docmoates: Add medication infobox (Drugbox) to monographs

Docmoates: NCLEX nursing pharmacology monographs — batch import